Knockdown NEK7 stimulates anti-tumor immune responses by NLRP3/PD-L1 signaling in esophageal cancer
In conclusion, NEK7 is a key regulator in the progression of esophageal cancer and the immune evasion. Targeting the NEK7/NLRP3 pathway may have therapeutic potential for the treatment of esophageal cancer.
Authors
- Yaoxian Xiang
- Li Wang (ORCID: https://orcid.org/0000-0001-5043-9626)
- Xin Liu (ORCID: https://orcid.org/0000-0002-5795-2948)
- Jing Wang (ORCID: https://orcid.org/0000-0002-9495-781X)
- Zhe Liu (ORCID: https://orcid.org/0000-0003-4726-2940)
- Weiqiang Li (ORCID: https://orcid.org/0000-0003-4741-6778)
- Yan Dong (ORCID: https://orcid.org/0000-0002-7833-0582)
- Kangjie Wang (ORCID: https://orcid.org/0009-0002-7063-5610)
- Yurong Cheng
Institutions
- Beijing Luhe Hospital Affiliated to Capital Medical University (CN)
- Tsinghua University (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-05-10
- DOI
- https://doi.org/10.1007/s00262-025-04057-5
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05